Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumococcal Vaccination in Aging Renal Transplant Recipients
NCT03802994Phase 1Terminated
- Sponsor
- VA Office of Research & Development
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Prevnar 13 in pneumococcal disease (5 arms), sponsored by VA Office of Research & Development. Primary endpoints: Anti-pneumococcal IgG Antibody Change at 30 days, Opsonophagocytic Antibody Titer Serum Dilution Difference at 30 days and 1 more. Started Nov 2018; status: terminated.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT03802994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802994.